Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID‐19 pandemic

Eşkazan, Ahmet Emre

doi:10.1111/bcp.14353

Cited by 8 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The management of patients with hematological malignancies including chronic myeloid leukemia (CML) can be challenging in the era of the coronavirus disease-19 (COVID-19) pandemic [ 1 ]. There are limited data published in the literature reporting the outcomes of CML patients with COVID-19 [ 2 , 3 ], so, herein, we share our experiences with the management of patients with CML with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection.…”

Section: To the Editormentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey

Yılmaz¹,

Pekmezci²,

Gül³

et al. 2021

Tjh

Self Cite

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 99%

“…CML can present unique problems during a SARS-CoV-2 infection [ 1 ]. Drug-drug interactions between TKIs and COVID-19 treatments can be hazardous and require careful monitoring.…”

Section: To the Editormentioning

confidence: 99%

COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey

Yılmaz¹,

Pekmezci²,

Gül³

et al. 2021

Tjh

Self Cite

View full text Add to dashboard Cite

“…They have proven to be efficacious in various chemotherapy treatments because of their ability to inhibit phosphorylation of amino acids, thereby playing a critical role in preventing the progression of several cancers. A large number of trials are being conducted on Nintedanib esilate, which is a small molecule kinase inhibitor whose use has primarily been approved in treatment of idiopathic pulmonary fibrosis 47,48 . Though results of the trials for their use in CoVid-19 are yet to come, these are highly targeted drugs and are being used in treating the comorbidities associated with the disease such as pulmonary fibrosis, hyperinflammation, pulmonary vascular leak, etc 49,50 .…”

Section: Kinase Inhibitorsmentioning

confidence: 99%

Therapeutic Modalities in the management of COVID-19: A worldwide landscape

Uttamani

Fernandes

Pandey³

et al. 2020

Preprint

View full text Add to dashboard Cite

Several strains of the novel Coronavirus have been identified and countries around the world are conducting research to identify, map and compare each type. Its infection can manifest with symptoms ranging from uncomplicated non-specific illness to a more damaging syndrome that include mild to moderate pneumonia (Co-vid 19 pneumonia broadly categorised into the phenotypes: L-type and H-type); Acute Respiratory Distress Syndrome; Sepsis and Septic shock. Although, this virus has a low mortality rate, the danger lies in its virulence and transmission dynamics. With more and more cases being reported, researchers and clinicians are promptly identifying and triaging the cases for treatment. Till date, there has been no drug identified to be efficacious cure for this infection. Using the WHO guidelines as a base, various medical institutions are continuously updating their guidelines for the identification and therapeutic management of persons infected with Co-vid 19, with a strong emphasis on IPC measures. The guidelines also highlight detailed supportive treatment including supplemental oxygen therapy, ventilation, intubation and management of specific complications. The current treatment is tailored to patient centred management for the existing co-morbidities and appreciate a progress in the prognosis. What is needed at this hour however, is a definitive drug therapy or vaccine. Different countries are rushing to find this and various trials are already underway. The aim of this article is thus to review salient features of specific therapies being used now and summarise the different clinical trials being conducted so as to stay abreast of the possible treatment modalities.

show abstract

“…MSCs has called for attention due to source potential, a high proliferation rate, the need of a less invasive procedure, and free of ethical issues. There is much superiority in using MSC therapy [39][40][41] fibrosis [42,43]. Though results of the trials for their use in CoVid-19 are yet to come, these are highly targeted drugs and are being used in treating the comorbidities associated with the disease such as pulmonary fibrosis, hyperinflammation, pulmonary vascular leak, etc [44,45].…”

Section: I) Mesenchymal Stem Cell Therapymentioning

confidence: 99%

Therapeutic Modalities in the Management of COVID-19: A Worldwide Landscape

Bhat¹,

Surabathula²,

Pandey³

et al. 2020

Dental

View full text Add to dashboard Cite

Several strains of the novel Coronavirus have been identified and countries around the world are conducting research to identify, map and compare each type. Its infection can manifest with symptoms ranging from uncomplicated nonspecific illness to a more damaging syndrome that include mild to moderate pneumonia (Covid-19 pneumonia broadly categorised into the phenotypes: L-type and H-type); Acute Respiratory Distress Syndrome; Sepsis and Septic shock.Although, this virus has a low mortality rate, the danger lies in its virulence and transmission dynamics. Until date, there has been no drug identified to be efficacious cure for this infection.Using the WHO (World Health Organization) guidelines as a base, various medical institutions are continuously updating their guidelines for the identification and therapeutic management of persons infected with Covid 19, with a strong emphasis on IPC measures. The guidelines also highlight detailed supportive treatment including supplemental oxygen therapy, ventilation, intubation and management of specific complications. The current treatment is tailored to patient centred management for the existing co-morbidities and appreciates a progress in the prognosis. The aim of this article is thus to review salient features of specific therapies being used now and summaries the different clinical trials being conducted so as to stay abreast of the possible treatment modalities.

show abstract

Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID‐19 pandemic

Cited by 8 publications

References 28 publications

COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey

COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey

Therapeutic Modalities in the management of COVID-19: A worldwide landscape

Therapeutic Modalities in the Management of COVID-19: A Worldwide Landscape

Contact Info

Product

Resources

About